Oluyemi Okupe Sells 12,651 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 12,651 shares of the business’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $16.79, for a total value of $212,410.29. Following the sale, the chief financial officer now owns 211,000 shares in the company, valued at approximately $3,542,690. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Oluyemi Okupe also recently made the following trade(s):

• On Tuesday, September 3rd, Oluyemi Okupe sold 11,609 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.60, for a total transaction of $169,491.40.
• On Tuesday, June 25th, Oluyemi Okupe sold 11,546 shares of Hims & Hers Health stock. The shares were sold at an average price of $22.21, for a total transaction of $256,436.66.

Hims & Hers Health Trading Up 5.0 %

Shares of NYSE:HIMS opened at $17.27 on Wednesday. Hims & Hers Health, Inc. has a 1 year low of $5.65 and a 1 year high of $25.74. The firm has a fifty day moving average price of $17.11 and a 200 day moving average price of $17.13. The stock has a market capitalization of $3.71 billion, a PE ratio of -1,727.00 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The company had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. During the same quarter in the prior year, the company posted ($0.03) EPS. The firm’s revenue was up 51.8% on a year-over-year basis. On average, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors have recently modified their holdings of the company. Nisa Investment Advisors LLC boosted its holdings in shares of Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after buying an additional 1,603 shares during the period. Quest Partners LLC boosted its holdings in Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after acquiring an additional 3,507 shares during the period. Van ECK Associates Corp acquired a new stake in shares of Hims & Hers Health in the second quarter valued at about $111,000. Belpointe Asset Management LLC increased its stake in shares of Hims & Hers Health by 10.0% in the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock worth $118,000 after purchasing an additional 1,205 shares during the period. Finally, Amalgamated Bank lifted its position in shares of Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after purchasing an additional 2,354 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

HIMS has been the subject of a number of research analyst reports. Piper Sandler restated a “neutral” rating and issued a $18.00 target price on shares of Hims & Hers Health in a report on Tuesday, August 6th. Needham & Company LLC assumed coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective for the company. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Bank of America dropped their target price on Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, September 13th. Finally, Jefferies Financial Group raised their price target on shares of Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, June 27th. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $19.86.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.